You are here: Industry Insights > CDMO

News List

Piramal Pharma Ltd. Invests Minority Stake in CDMO Yapan Bio contractpharma
December 22, 2021
The investment of INR 101.77 cror in biologics reflects the company’s global commitment to this fast-growing segment of the pharma industry.
Bora Pharmaceuticals collaborates with Taishin Holdings to launch CDMO investment and M&A plan prnasia
December 09, 2021
Bobby Sheng, chairman of Bora Pharmaceuticals (6472.TWO), today announced a partnership with Taishin Healthcare Limited Partnership at the 2021 Biotech Investor Forum...
Vetter Wins Frost & Sullivan’s 2021 Global Customer Value Leadership Award, and Looks Back on a Stable Year Under Ongoing Pandemic Circumstances B3Cnewswire
December 08, 2021
Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), has been awarded the Frost & Sullivan's 2021 Global Customer Value Leadership Award in the aseptic fill & finish market...
Adare Pharma acquires oral formulations specialist Frontida BioPharm CPhIonline
December 06, 2021
The combined company intends to lead in the space of oral formulations, solving customers' complex formulation challenges.
ST Pharm to construct second oligonucleotide facility in Korea CPhIonline
December 03, 2021
The expansion is expected to make the company the largest CDMO in oligonucleotide production in 2025.
ANI Pharma enhances generics and CDMO business through Novitium acquisition CPhIonline
November 29, 2021
The transaction expands ANI’s R&D pipeline and adds nine new customers to its growing CDMO business.
Micro-Sphere Expands Capabilities with $3.5M Investment ContractPharma
November 09, 2021
Micro-Sphere has added to its contract development and manufacturing expertise with new spray drying technology and increased high containment capabilities.
GTP Bioways to galvanise CDMO position in France with two new biopharma facilities CPhIonline
October 29, 2021
The specialist biotherapies and nanotherapies producer has said the first line, which will have a capacity of 300 L, will focus on production using microbial systems (bacteria and yeast), and will be operational in early 2023.
Catalent embarks on $230M viral vector expansion project at Harmans campus CPhIonline
October 28, 2021
CDMO Catalent is to spend $230 million on adding three further commercial-scale viral vector manufacturing suites and associated support facilities and services at its gene therapy campus in Harmans, Maryland.
Forge Biologics to provide CDMO support for Solid Biosciences' preclinical gene therapy CPhIonline
October 10, 2021
By providing AAV process development, scale up and cGMP manufacturing services, Forge hopes to bolster Solid's gene therapy pipeline

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page